YR

Yogesh Rai

Active Director Director DIN 10149946
DIN 10149946 First appointment May 2023 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2023
Shareholding value β€’β€’β€’β€’ Premium profile

About Yogesh Rai

Data last updated:

Yogesh Rai is a Director at Cadomack Pharmaceuticals India Private Limited (since 2023). The company operates in Paper.

DIN 10149946
Primary Designation Director
Industry Paper
First Appointment 06 May 2023
Oldest Company Age 3 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director06 May 20232023Active

Directorship timeline

Open interactive timeline →
Cadomack Pharmaceuticals India Private Limited
Premium access

Shareholding and investment profile for Yogesh Rai

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Yogesh Rai

Yogesh Rai currently holds 1 directorship: Cadomack Pharmaceuticals India Private Limited (Director, since 06 May 2023).

Yogesh Rai was first appointed on 06 May 2023 as Director at Cadomack Pharmaceuticals India Private Limited.

The current boards of Yogesh Rai's companies include Dharmaraj Shankar (Cadomack Pharmaceuticals India Private Limited), Eaytheshyam (Cadomack Pharmaceuticals India Private Limited), Jarish Kaibele Kariappa (Cadomack Pharmaceuticals India Private Limited), Srikanta Murthy Siddaiah Mahadeva (Cadomack Pharmaceuticals India Private Limited), Vinay Veerappa (Cadomack Pharmaceuticals India Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available